Oncology Central

ESMO18: New combination therapy for breast cancer may prolong survival

A major clinical trial has found that combining a targeted drug with hormone therapy can substantially extend survival for women with advanced breast cancer and may delay the need for chemotherapy.

The clinical trial, named PALOMA-3, tested the new method of treatment on women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. At this stage currently the only available option is chemotherapy, which can have debilitating side-effects.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.